Home › Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence
 

Keywords :   


Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence

2016-06-09 23:04:32| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss ZINPLAVA (bezlotoxumab), an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence. The Advisory Committee agreed, with a vote of 10 to 5 with one abstention, that Merck has provided substantial evidence of the safety and effectiveness of bezlotoxumab for the prevention of C. Language: English read more

Tags: statement agent meeting committee

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
03.05Navigator Paper Ups Offer for Accrual
03.05Dilo Hosts Open House
03.05Spate Releases Top-Rising Skin Care Ingredients Report with Grant Industries
03.05Fedrigoni Self-Adhesives introduces compostable label material
More »